Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma | 2 | 2022 | 215 | 0.920 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2020 | 110 | 0.810 |
Why?
|
| Carcinoma, Medullary | 1 | 2019 | 7 | 0.700 |
Why?
|
| Sickle Cell Trait | 1 | 2019 | 24 | 0.690 |
Why?
|
| Lupus Nephritis | 4 | 2021 | 193 | 0.650 |
Why?
|
| Femur | 2 | 2018 | 113 | 0.650 |
Why?
|
| Brain Concussion | 1 | 2018 | 27 | 0.630 |
Why?
|
| Ossification, Heterotopic | 1 | 2018 | 45 | 0.630 |
Why?
|
| Placenta Diseases | 1 | 2015 | 5 | 0.550 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2015 | 16 | 0.540 |
Why?
|
| Anemia, Sickle Cell | 1 | 2019 | 364 | 0.520 |
Why?
|
| Kidney | 5 | 2021 | 945 | 0.460 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 1533 | 0.420 |
Why?
|
| Eyelid Neoplasms | 2 | 2022 | 12 | 0.400 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2022 | 16 | 0.400 |
Why?
|
| Neuraminidase | 3 | 2021 | 36 | 0.400 |
Why?
|
| Mesangial Cells | 2 | 2021 | 37 | 0.350 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2020 | 306 | 0.300 |
Why?
|
| Synovitis | 1 | 2022 | 8 | 0.220 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2022 | 18 | 0.210 |
Why?
|
| Osteoarthritis, Knee | 1 | 2022 | 26 | 0.210 |
Why?
|
| Female | 14 | 2022 | 38015 | 0.210 |
Why?
|
| Tool Use Behavior | 1 | 2021 | 4 | 0.210 |
Why?
|
| Rhabdoid Tumor | 1 | 2021 | 9 | 0.200 |
Why?
|
| Humans | 18 | 2022 | 68525 | 0.200 |
Why?
|
| Breast | 1 | 2022 | 137 | 0.200 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 1139 | 0.190 |
Why?
|
| Misoprostol | 1 | 2020 | 6 | 0.190 |
Why?
|
| Povidone | 1 | 2020 | 12 | 0.190 |
Why?
|
| Lymph Nodes | 1 | 2022 | 258 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 1 | 2022 | 369 | 0.190 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 1 | 2020 | 8 | 0.190 |
Why?
|
| Cellulose | 1 | 2020 | 22 | 0.190 |
Why?
|
| Embolization, Therapeutic | 1 | 2022 | 150 | 0.180 |
Why?
|
| Parotid Neoplasms | 1 | 2020 | 49 | 0.180 |
Why?
|
| Amniotic Fluid | 1 | 2019 | 30 | 0.180 |
Why?
|
| Glycosphingolipids | 1 | 2020 | 51 | 0.180 |
Why?
|
| Placenta | 1 | 2020 | 101 | 0.180 |
Why?
|
| Allografts | 1 | 2019 | 63 | 0.180 |
Why?
|
| Bronchial Neoplasms | 1 | 2019 | 12 | 0.170 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 63 | 0.170 |
Why?
|
| Plasmacytoma | 1 | 2019 | 15 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 1 | 2019 | 69 | 0.170 |
Why?
|
| Bronchi | 1 | 2019 | 59 | 0.170 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 206 | 0.160 |
Why?
|
| Polysaccharides | 1 | 2020 | 176 | 0.160 |
Why?
|
| Premature Birth | 1 | 2019 | 148 | 0.160 |
Why?
|
| Femoral Neoplasms | 1 | 2017 | 7 | 0.150 |
Why?
|
| Fibrosarcoma | 1 | 2017 | 21 | 0.150 |
Why?
|
| Pathology | 1 | 2017 | 17 | 0.150 |
Why?
|
| Glutamyl Aminopeptidase | 1 | 2017 | 12 | 0.150 |
Why?
|
| Bronchoscopy | 1 | 2019 | 147 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 334 | 0.150 |
Why?
|
| Pregnancy | 3 | 2020 | 2331 | 0.150 |
Why?
|
| Cytokines | 1 | 2021 | 866 | 0.140 |
Why?
|
| Certification | 1 | 2017 | 66 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 2323 | 0.140 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 493 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2017 | 330 | 0.140 |
Why?
|
| Connective Tissue Diseases | 1 | 2015 | 18 | 0.140 |
Why?
|
| Kidney Glomerulus | 1 | 2017 | 155 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 28 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2017 | 307 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2017 | 657 | 0.100 |
Why?
|
| Mucins | 2 | 2022 | 22 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 839 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 1172 | 0.100 |
Why?
|
| Male | 6 | 2022 | 37281 | 0.090 |
Why?
|
| Tissue Array Analysis | 2 | 2020 | 53 | 0.090 |
Why?
|
| Mice, Inbred MRL lpr | 2 | 2020 | 118 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2022 | 2550 | 0.080 |
Why?
|
| Biopsy | 2 | 2019 | 539 | 0.080 |
Why?
|
| Young Adult | 1 | 2018 | 5708 | 0.070 |
Why?
|
| Adult | 3 | 2020 | 21375 | 0.070 |
Why?
|
| Animals | 5 | 2022 | 20877 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2022 | 7264 | 0.060 |
Why?
|
| Mice | 3 | 2021 | 8472 | 0.060 |
Why?
|
| Sweat Glands | 1 | 2022 | 10 | 0.050 |
Why?
|
| Sheep | 1 | 2022 | 128 | 0.050 |
Why?
|
| Knee Joint | 1 | 2022 | 115 | 0.050 |
Why?
|
| Arteries | 1 | 2022 | 108 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2021 | 76 | 0.050 |
Why?
|
| Laboratories | 1 | 2021 | 44 | 0.050 |
Why?
|
| Excipients | 1 | 2020 | 8 | 0.050 |
Why?
|
| Administration, Intravaginal | 1 | 2020 | 11 | 0.050 |
Why?
|
| Forensic Pathology | 1 | 2020 | 19 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 2222 | 0.050 |
Why?
|
| Middle Aged | 4 | 2020 | 21119 | 0.050 |
Why?
|
| Phosphorous Acids | 1 | 2020 | 4 | 0.050 |
Why?
|
| Oseltamivir | 1 | 2020 | 6 | 0.050 |
Why?
|
| G(M3) Ganglioside | 1 | 2020 | 7 | 0.050 |
Why?
|
| Neck Dissection | 1 | 2020 | 55 | 0.050 |
Why?
|
| Fucosyltransferases | 1 | 2020 | 6 | 0.050 |
Why?
|
| Hydroxylation | 1 | 2020 | 41 | 0.050 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2020 | 24 | 0.050 |
Why?
|
| Lactosylceramides | 1 | 2020 | 27 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 38 | 0.050 |
Why?
|
| Organ Size | 1 | 2020 | 242 | 0.050 |
Why?
|
| Proline | 1 | 2020 | 52 | 0.050 |
Why?
|
| Sewage | 1 | 2019 | 23 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 247 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 120 | 0.050 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2020 | 39 | 0.040 |
Why?
|
| Glycomics | 1 | 2020 | 29 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 274 | 0.040 |
Why?
|
| Proteinuria | 1 | 2020 | 136 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 139 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 238 | 0.040 |
Why?
|
| Glycosylation | 1 | 2020 | 185 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 444 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2021 | 453 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 455 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 211 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2019 | 109 | 0.040 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2017 | 7 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2019 | 211 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2017 | 24 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2017 | 94 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 191 | 0.040 |
Why?
|
| Collagen | 1 | 2020 | 636 | 0.040 |
Why?
|
| Tibia | 1 | 2017 | 93 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 365 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 179 | 0.030 |
Why?
|
| Ceramides | 1 | 2020 | 578 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1341 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 756 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2017 | 682 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2017 | 254 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 481 | 0.030 |
Why?
|
| Infant | 1 | 2021 | 2891 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 2790 | 0.030 |
Why?
|
| Cell Line | 1 | 2017 | 1752 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2019 | 2453 | 0.030 |
Why?
|
| Contrast Media | 1 | 2017 | 594 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3702 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2017 | 1173 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 1026 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 1692 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2017 | 596 | 0.020 |
Why?
|
| Rats | 1 | 2017 | 5300 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 2688 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 7028 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 8903 | 0.020 |
Why?
|
| United States | 1 | 2017 | 7335 | 0.020 |
Why?
|
| Aged | 1 | 2020 | 14842 | 0.020 |
Why?
|